Financials Brainstorm Cell Therapeutics Inc. Deutsche Boerse AG
Equities
GHDN
US10501E2019
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.465 EUR | -5.01% | -6.44% | +102.17% |
Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 | CI |
Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Management Changes | CI |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 96.76 | 142.8 | 145.1 | 59.93 | 13.37 | 36.88 | - | - |
Enterprise Value (EV) 1 | 96.76 | 142.8 | 145.1 | 59.93 | 13.37 | 36.88 | 36.88 | 36.88 |
P/E ratio | -4.04 x | -4.23 x | -5.88 x | -2.48 x | -0.68 x | -1.93 x | -1.44 x | -1.3 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 22,606 | 31,568 | 36,278 | 36,542 | 48,982 | 68,342 | - | - |
Reference price 2 | 4.280 | 4.525 | 4.000 | 1.640 | 0.2730 | 0.5396 | 0.5396 | 0.5396 |
Announcement Date | 2/18/20 | 2/4/21 | 3/28/22 | 3/30/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -23 | -31.68 | -24.54 | -24.82 | -21.44 | -21.9 | -27.43 | -31.1 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -23.25 | -31.81 | -24.46 | -24.28 | -17.19 | -21.9 | -27.43 | -31.1 |
Net income 1 | -23.25 | -31.81 | -24.46 | -24.28 | -17.19 | -21.9 | -27.43 | -31.1 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | -1.060 | -1.070 | -0.6800 | -0.6600 | -0.4000 | -0.2800 | -0.3750 | -0.4150 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 2/18/20 | 2/4/21 | 3/28/22 | 3/30/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -5.277 | -6.212 | -5.475 | -7.591 | -6.841 | -4.915 | -5.151 | -5.449 | -6.035 | -4.804 | -4.5 | -5.2 | -5.8 | -6.4 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -5.336 | -6.19 | -5.36 | -7.041 | -6.858 | -5.018 | -5.059 | -5.329 | -1.226 | -5.578 | -4.5 | -5.2 | -5.8 | -6.4 |
Net income 1 | -5.336 | -6.19 | -5.36 | -7.041 | -6.858 | -5.018 | -5.059 | -5.329 | -1.226 | -5.578 | -4.5 | -5.2 | -5.8 | -6.4 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1500 | -0.1700 | -0.1500 | -0.1900 | -0.1900 | -0.1300 | -0.1400 | -0.1300 | -0.0300 | -0.1100 | -0.0700 | -0.0700 | -0.0600 | -0.0700 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/15/21 | 3/28/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/30/23 | 5/15/23 | 8/14/23 | 11/14/23 | 4/1/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 2/18/20 | 2/4/21 | 3/28/22 | 3/30/23 | 4/1/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.58% | 42.86B | |
+12.01% | 42.74B | |
+45.09% | 41.36B | |
-8.83% | 27.68B | |
+7.75% | 25.15B | |
-23.08% | 18.63B | |
+29.97% | 12.37B | |
-1.98% | 11.92B | |
+7.95% | 11.21B |
- Stock Market
- Equities
- BCLI Stock
- GHDN Stock
- Financials Brainstorm Cell Therapeutics Inc.